What was the growth rate for the company's proteomics business in 2019-Q3
 components and biopharma research and microbiology looks pretty good. Maybe NMR booking is a little weaker after they were growing at a wonderful pace last year.
Overall, China, good revenue growth, a little bit slower order growth this year than last year. Many signals that you get overall. The specific question, the high-end research funding, we think continues very much. I think that remains a top priority for China is my impression.
Derik De Bruin -- Bank of America Merrill Lynch -- Analyst
Thank you.
Operator
And our next question will come from Doug Schenkel with Cowen. Please go ahead.
Chris Lin -- Cowen and Company -- Analyst
Hey. This is Chris on for Doug. I just want to start with Calid. so Calid growth has accelerated meaningfully this year to double digits.
I think you talked about the mass spec portfolio refresh and diagnostics driving an improvement in growth. But curious if there were any other dynamics. And not looking for 2020 guidance, but how sustainable do you think this growth is? And if we were to use a baseball analogy, what inning do you think you're in, in terms of the new instrument placement cycle?
Frank Laukien -- President and Chief Executive Officer
So mass spectrometry and Maldi Biotyper do very well. Maldi Biotyper is in the baseball game for sure. That's clinical diagnostics. It's just all a need in a relatively steady market.
And we have really great solutions there, and they have more and more capabilities. We're perhaps even winning market share there. And the Hain acquisition, by and large, is going well. There are more things in the pipeline for U.S.
FDA clearance of certain additional capabilities. So that very steady business, and we're delighted that even the instrument part of that business is sort of back to the low teens. And the consumables business there continues to grow well north of 20%. So very solid, no end in sight, no final inning coming up there.
Proteomics. I don't know. I think where roughly where genomics was 10, 12 years ago. I'm not saying that proteomics will necessarily be as big as genomics in total.
But again, no baseball analogy there at all. I think these markets are healthy. And our technology is becoming more and more appreciated there. So no runway, no baseball games.
These metaphors really don't apply to these markets.
Chris Lin -- Cowen and Company -- Analyst
OK. And then, Gerald, could you just help us bridge the EPS guidance for the year? I think you beat Q3 by $0.06 and then you increased the full-year EPS guidance by $0.02. The implied Q4 EPS growth rate is I think only about 4%, which is a meaningful slowdown relative to the 20.9% rate you posted on a year-to-date basis. So clearly, there has been some nice momentum this year.
Just really want to make sure we're not missing anything here and updated EPS guidance is, I guess, an effort to derisk guidance for the full year.
Gerald Herman -- Chief Financial Officer
Well, I guess what I'd say is that we posted very solid performance on an EPS perspective over the first 9 months. And we feel like we should clearly provide some of it into our updated guidance for the full year at this stage. Clearly, we're generating good profitability from the numbers we've posted thus far. So I think we're just moving it in a reasonable range at the moment.
I don't think there's anything special that I really want to highlight other than we continue to drive operating margin performance. The mix being driven by our product is helping for sure. And more to come is the expectation.
Chris Lin -- Cowen and Company -- Analyst
OK. Sorry. And just quickly last question. I think you know that you have strong growth in Japan.
Some of your peers talked about potentially benefiting from a pull-forward of orders due to the increase in Japan value-added tax. Did that -- the dynamic impact you at all? If not, how sustainable is the Japan growth here?
Frank Laukien -- President and Chief Executive Officer
Yes. We're -- we don't have any data that would allow us to estimate whether it was a partial effect or material at all. Keep in
 components and biopharma research and microbiology looks pretty good. Maybe NMR booking is a little weaker after they were growing at a wonderful pace last year.
Overall, China, good revenue growth, a little bit slower order growth this year than last year. Many signals that you get overall. The specific question, the high-end research funding, we think continues very much. I think that remains a top priority for China is my impression.
Derik De Bruin -- Bank of America Merrill Lynch -- Analyst
Thank you.
Operator
And our next question will come from Doug Schenkel with Cowen. Please go ahead.
Chris Lin -- Cowen and Company -- Analyst
Hey. This is Chris on for Doug. I just want to start with Calid. so Calid growth has accelerated meaningfully this year to double digits.
I think you talked about the mass spec portfolio refresh and diagnostics driving an improvement in growth. But curious if there were any other dynamics. And not looking for 2020 guidance, but how sustainable do you think this growth is? And if we were to use a baseball analogy, what inning do you think you're in, in terms of the new instrument placement cycle?
Frank Laukien -- President and Chief Executive Officer
So mass spectrometry and Maldi Biotyper do very well. Maldi Biotyper is in the baseball game for sure. That's clinical diagnostics. It's just all a need in a relatively steady market.
And we have really great solutions there, and they have more and more capabilities. We're perhaps even winning market share there. And the Hain acquisition, by and large, is going well. There are more things in the pipeline for U.S.
FDA clearance of certain additional capabilities. So that very steady business, and we're delighted that even the instrument part of that business is sort of back to the low teens. And the consumables business there continues to grow well north of 20%. So very solid, no end in sight, no final inning coming up there.
Proteomics. I don't know. I think where roughly where genomics was 10, 12 years ago. I'm not saying that proteomics will necessarily be as big as genomics in total.
But again, no baseball analogy there at all. I think these markets are healthy. And our technology is becoming more and more appreciated there. So no runway, no baseball games.
These metaphors really don't apply to these markets.
Chris Lin -- Cowen and Company -- Analyst 
OK. And then, Gerald, could you just help us bridge the EPS guidance for the year? I think you beat Q3 by $0.06 and then you increased the full-year EPS guidance by $0.02. The implied Q4 EPS growth rate is I think only about 4%, which is a meaningful slowdown relative to the 20.9% rate you posted on a year-to-date basis. So clearly, there has been some nice momentum this year.
Just really want to make sure we're not missing anything here and updated EPS guidance is, I guess, an effort to derisk guidance for the full year.
Gerald Herman -- Chief Financial Officer
Well, I guess what I'd say is that we posted very solid performance on an EPS perspective over the first 9 months. And we feel like we should clearly provide some of it into our updated guidance for the full year at this stage. Clearly, we're generating good profitability from the numbers we've posted thus far. So I think we're just moving it in a reasonable range at the moment.
I don't think there's anything special that I really want to highlight other than we continue to drive operating margin performance. The mix being driven by our product is helping for sure. And more to come is the expectation.
Chris Lin -- Cowen and Company -- Analyst
OK. Sorry. And just quickly last question. I think you know that you have strong growth in Japan.
Some of your peers talked about potentially benefiting from a pull-forward of orders due to the increase in Japan value-added tax. Did that -- the dynamic impact you at all? If not, how sustainable is the Japan growth here?
Frank Laukien -- President and Chief Executive Officer
Yes. We're -- we don't have any data that would allow us to estimate whether it was a partial effect or material at all. Keep in